XOMA (XOMA)

Company Profile

xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.

Company profile

Ticker

XOMA, XOMAP, XOMAO

Exchange

NASDAQ

Website

www.xoma.com/

CEO

James Neal

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies • Celgene ...

Former names

XOMA CORP /DE/, XOMA LTD /DE/

SEC CIK

0000791908

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

XOMA Technology Ltd. • XOMA (US) LLC • XOMA UK Limited ...

IRS number

942756657

XOMA stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

7 Nov 23

XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value

Termination of a Material Definitive Agreement

8 Aug 23

XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy

Entry into a Material Definitive Agreement

22 Jun 23

Latest ownership filings

View all

Financial summary

Financial statements Chart XOMA financial data

Quarter (USD)	Sep 23	Jun 23	Mar 23	Dec 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	33.47 mm	33.47 mm	33.47 mm	33.47 mm	33.47 mm	33.47 mm
Cash burn (monthly)	(no burn)	3.73 mm	1.93 mm	2.34 mm	699.67 k	1.51 mm
Cash used (since last report)	n/a	8.06 mm	4.17 mm	5.06 mm	1.51 mm	3.26 mm
Cash remaining	n/a	25.41 mm	29.31 mm	28.41 mm	31.96 mm	30.21 mm
Runway (months of cash)	n/a	6.8	15.2	12.1	45.7	20.0

Beta Read what these cash burn values mean

Financial data from XOMA earnings reports.

Institutional ownership, Q2 2023

XOMA institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	58	49	+18.4%
Opened positions	15	7	+114.3%
Closed positions	6	8	-25.0%
Increased positions	19	17	+11.8%
Reduced positions	8	10	-20.0%

13F shares	Current	Prev Q	Change
Total value	135.55 bn	143.06 bn	-5.2%
Total shares	11.57 mm	10.91 mm	+6.0%
Total puts	2.30 k	700.00	+228.6%
Total calls	11.40 k	1.90 k	+500.0%
Total put/call ratio	0.2	0.4	-45.2%

Largest owners	Shares	Value	Change
BVF	3.63 mm	$68.64 bn	0.0%
Biotechnology Value Fund L P	3.53 mm	$144.08 mm	0.0%
FMR	1.18 mm	$22.36 bn	-4.1%
NVS Novartis	539.13 k	$8.76 mm	0.0%
BLK Blackrock	428.74 k	$8.10 bn	+252.0%
Vanguard	411.41 k	$7.77 bn	+7.5%
Stonepine Capital Management	349.40 k	$6.60 bn	+9.8%
Opaleye Management	275.00 k	$594.75 mm	+13.2%
Geode Capital Management	153.90 k	$2.91 bn	+88.4%
Acuitas Investments	137.13 k	$2.59 bn	+57.8%

Largest transactions	Shares	Bought/sold	Change
BLK Blackrock	428.74 k	+306.94 k	+252.0%
STT State Street	127.38 k	+87.10 k	+216.3%
Geode Capital Management	153.90 k	+72.22 k	+88.4%
Moore Capital Management	52.10 k	+52.10 k	NEW
Susquehanna International	0.00	-50.53 k	EXIT
Acuitas Investments	137.13 k	+50.23 k	+57.8%
FMR	1.18 mm	-50.15 k	-4.1%
Millennium Management	46.94 k	+46.94 k	NEW
NTRS Northern Trust	86.08 k	+44.23 k	+105.7%
Renaissance Technologies	47.10 k	+35.50 k	+306.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

XOMA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
3 Oct 23	Bradley Sitko	Common Stock	Buy	Acquire P	No	No	13.89	250	3.47 k	5,600
2 Oct 23	Bradley Sitko	Common Stock	Buy	Acquire P	No	No	14.25	1,500	21.38 k	5,350
2 Oct 23	Owen Hughes	Common Stock	Buy	Acquire P	No	No	13.83	1,000	13.83 k	3,500
26 Sep 23	Owen Hughes	Common Stock	Buy	Acquire P	No	No	14.43	2,499	36.06 k	2,500
25 Sep 23	Owen Hughes	Common Stock	Buy	Acquire P	No	No	14.65	1	14.65	1
31 May 23	Bradley Sitko	Common Stock	Buy	Acquire P	Yes	No	17.2	1,000	17.20 k	3,500
31 May 23	Bradley Sitko	Common Stock	Buy	Acquire P	Yes	No	17	500	8.50 k	2,500
24 May 23	Owen Hughes	Depositary Shares - 8.375% B Cumulative Stock	Buy	Acquire P	No	No	23.79	1,032	24.55 k	2,000
23 May 23	Owen Hughes	Depositary Shares - 8.375% B Cumulative Stock	Buy	Acquire P	No	No	23.49	768	18.04 k	968
23 May 23	Owen Hughes	Depositary Shares - 8.375% B Cumulative Stock	Buy	Acquire P	No	No	23.33	200	4.67 k	200